Personalis reported a 30% year-over-year rise in second-quarter revenue driven by higher pharma testing and clinical test growth, while awaiting acquisition by Tempus AI under an agreement valued around $1.5 billion. The company highlighted increased covered lung cancer testing and expanded Medicare coverage for immune-oncology therapy monitoring. Personalis also secured Medicare approval for its NeXT Personal assay for monitoring response to neoadjuvant therapy in selected stage II–III triple-negative or HER2-positive breast cancer. The company delivered over 10,000 clinical tests in the quarter and reported higher R&D spending. For diagnostics buyers and biopharma users, the update reflects ongoing payer expansion for genomic monitoring workflows—important for scaling adoption of companion diagnostics and liquid/genomic testing services.